NODA-FGLP21
NODA-FGLP21 is a tumor-targeting agent and a fibrinogen-like protein 1 (FGL1) binder. NODA-FGLP21 specifically binds to FGL1, and this binding is competitively inhibited by unlabeled FGLP21. NODA-FGLP21 can be used in the research of liver cancer.
For research use only. We do not sell to patients.
- Formula: C71H115N23O20S
- Molecular Weight:1642.88
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
NODA-FGLP21 (68Ga) (100 μg NODA-FGLP21 precursor, 370 MBq 68Ga; 10 min at 60 °C, 0.5-2 h at 37 °C) can be efficiently radiolabeled with high purity and specific activity, and maintains stability in PBS and serum for up to 2 h at 37 °C[1].
NODA-FGLP21 (68Ga) (37 kBq, 1 μM unlabeled FGLP21 for blocking; 30-120 min at 37 °C) shows specific, high uptake in FGL1-positive Huh7 human hepatocarcinoma cells (1.10 % AD/105 cells at plateau) and minimal uptake in FGL1-negative U87 MG human glioma cells, with uptake in Huh7 cells significantly reduced by unlabeled FGLP21[1].
NODA-FGLP21 (68Ga) (37 kBq, 0.01 nM-100 μM unlabeled FGLP21; 2 h at 37 °C) binds to FGL1 on Huh7 human hepatocarcinoma cells with an IC50 of 101.0 nM, indicating specific, moderate-affinity binding[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
NODA-FGLP21 (68Ga) (5.0 MBq; i.v.; single dose) shows low uptake in FGL1-negative U87 MG xenografts, with tumor uptake of 0.82% ID/g at 30 min post-injection, confirming its specificity for FGL1-expressing tumors[1].
NODA-FGLP21 (68Ga) (18.5 MBq; i.v.; single dose) causes no significant acute histopathological damage to major organs in healthy Balb/c mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NCG mice (6-8 weeks old, subcutaneous implantation of Huh7 human hepatocarcinoma cells)[1]
-
Dosage:5.0 MBq (68Ga-NODA-FGLP21); 10 mg/kg (unlabeled FGLP21, blocking studies)
-
Administration:i.v.; single dose
-
Result:Reached tumor uptake of 3.48% ID/g at 30 min post-injection, with a tumor-to-blood ratio of 2.37 and tumor-to-muscle ratio of 17.85.
Achieved tumor uptake of 2.85% ID/g at 60 min post-injection, with a tumor-to-blood ratio of 8.08 and tumor-to-muscle ratio of 21.5.
Attained tumor uptake of 1.70% ID/g at 120 min post-injection, with a tumor-to-blood ratio of 16.5 and tumor-to-muscle ratio of 32.5.
Reduced tumor uptake to 0.94% ID/g at 30 min post-injection when co-administered with unlabeled FGLP21.
Detected no significant radioactivity (less than 2% ID/g) in normal organs except kidneys, which showed uptake of 20.00% ID/g at 30 min post-injection.
-
Animal Model:NCG mice (6-8 weeks old, subcutaneous implantation of U87 MG human glioma cells)[1]
-
Dosage:5.0 MBq (68Ga-NODA-FGLP21)
-
Administration:i.v.; single dose
-
Result:Reached tumor uptake of 0.82% ID/g at 30 min post-injection, with a tumor-to-blood ratio of 0.70 and tumor-to-muscle ratio of 4.20.
Detected kidney uptake of 24.40% ID/g at 30 min post-injection; all other normal organs showed uptake less than 2% ID/g.
-
Animal Model:Balb/c mice (6-8 weeks old)[1]
-
Dosage:18.5 MBq (68Ga-NODA-FGLP21)
-
Administration:i.v.; single dose
-
Result:Observed no macroscopic lesions in major organs.
Detected no significant histopathological damage in major organs (heart, liver, spleen, lung, kidney) compared to saline-injected controls.
Chemical Information
-
Molecular Weight 1642.88
-
Formula C71H115N23O20S
-
Sequence
NODA-Ala-Ala-Val-His-Leu-Arg-Asp-Arg-Ala-Leu
-
Sequence Shortening
NODA-AAVHLRDRAL
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NODA-FGLP21 Related Classifications
HY-P11931 Related Classifications
Powered by Bioz